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Abstract
Uncaria tomentosa, commonly known as Cat’s claw, is a medicinal plant native 
to Peru.  It has been used for decades in the treatment of various inflammatory disorders.  
Treatment with Uncaria tomentosa has been shown to have effective anti-inflammatory 
activities.  Recent studies show that treatment of cells with extracts of Uncaria tomentosa
can inhibit the MAP kinase, Akt, and Wnt signaling pathways, suggesting it has specific 
anticancer therapeutic properties.  Previous work from our laboratory has shown that the 
effect of Uncaria tomentosa on the monocyte-like THP-1 cell line can block activation of 
these immune cells.  We are now investigating the effect of the Uncaria tomentosa as an 
anti-cancer therapy.  We have shown that Uncaria tomentosa can inhibit the growth of
cell cultures and can induce apoptosis in the murine melanoma cell line B16- BL6.  
Extracts of Uncaria tomentosa with 70% ethanol were more efficient at inducing 
apoptosis than aqueous extracts.  Apoptosis induction was evident as early as 24 h after 
treatment and almost all cells treated with the ethanolic extract of Uncaria tomentosa
were apoptotic by 72h.  Treatment with Uncaria tomentosa caused an increase in DNA 
fragmentation (TUNEL assay), caspase-3 cleavage, sub G1 peaks in flow cytometry, and 
apoptotic morphology.  Our experimental results indicate that Uncaria tomentosa can 
effectively kill melanoma cancer cells in vitro, in a dose-dependent manner, by enhancing 
apoptosis.   
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1Chapter 1:  Introduction
1.1. Cancer 
Cancer is a major public health problem and it is the main cause of death in many 
parts of the world.  In Canada, cancer is the second leading cause of death.  According to 
Canadian statistics, 2 of 5 Canadians will be diagnosed with cancer and 1 in 4 Canadians 
will die from cancer.  In 2013, it was estimated that 187,600 Canadians will develop 
cancer in their lifetime and 75,500 will die from it.  The concern of that is 52% of new 
cancer cases will be lung, breast, and prostate, which are considered to be the main 
cancer types that cause death.  Moreover, in Canada, men are diagnosed with cancer 
more often than women and most of them are over the age of 50 years.  Based on these 
statistics, the cancer cases among the Canadian population will increase from 34.9 
million cases in 2012 to 47.7 million cases by 2036.  These statistics are also important 
for planning health services for cancer patients in the future and provides incentives to 
increase cancer research to discover therapies that cure and prevent cancer in order to 
improve survival rates (1).
Cancer is one the diseases that develops by going through a multistep process (7). 
First, the transformation of normal cells to neoplastic cancer cells is widely studied in 
order to understand the causes of cancer progression (2).  The initiation of carcinogenesis 
is usually associated with environmental stressors that require a long and repeated 
exposure to many exogenous agents such as chemicals, radiation, poor diet, risky life 
styles, and individual habits (2).  This process can also be affected by intracellular factors 
2such as hormones, family history, and a genetic predisposition (7).  In addition, viruses, 
chromosomal abnormalities, non-healing wounds, and failure of immunological 
surveillance can also promote cancer risk (4).  Generally, carcinogenic promoters will 
cause a modification in the DNA sequence which can generate mutations that are 
involved in the development of cancer (4).  These mutations, which are the first 
phenomena associated with cancer disease, usually involve neoplastic genome mutations 
that affect the genes that are involved in controlling cellular proliferation, cellular 
development, apoptosis, and differentiation (7).  Complete transformation, the next step 
in developing a malignant cell is called the progression step in cancer development (7).  
According to this idea, cancer is defined as a genetic disease (5) caused by mutations in 
critical genes that result in uncontrolled cell proliferation or division (4) and decreased 
expression of programmed cell death (apoptosis) (6).  Cancer cells can be characterized 
by several specific properties such as loss of specialization, de-differentiation, loss of the 
normal interaction with the basement membrane, and the ability to move and invade other 
organs to form a new malignant tumor, called metastasis (11).  The metastatic ability of a 
cancer cell allows cancer to occur in every organ (12).
One of the most important cancer characteristics is metastasis, or invasion, which 
is considered to be the main cause of death because from cancer.  This idea of metastasis 
is when the tumor cells lose their ability to adhere to each other and migrate from the 
primary tumor site to surrounding tissue and then grow to form a new tumor in the new 
tissue (9).  One main mechanism in the metastatic process is Epithelial Mesenchymal 
Transition (EMT).  EMT occurs when cancer cells lose adhesion to each other (via E-
cadherin downregulation) and increase adhesion to the basement membrane promoting
3cell migration.  Ultimately, the basement membrane will be fragmented because of the 
increased secretion of proteases during cancer progression.  After the cells migrate from 
their primary tissue, they can enter the blood or lymph vessel, and then spread to distant 
or neighboring tissues.  Once in the new tissue the cells then return to their original 
epithelial morphology by Mesenchymal-Epithelial Transition (MET) and grow to form 
new tumors (10).
Figure 1.1: The main mechanism in the metastatic process (Epithelial
Mesenchymal Transition, EMT)
1.2. Cancer therapy
The second step after cancer diagnosis is determining an appropriate approach to 
treatment.  The ethical idea of figuring out which treatment method is suitable for each 
patient requires a plan to minimize the pain and discomfort experienced by the patient 
while expanding the patients’ lifespan.  Traditionally, the three common form of cancer 
treatment are surgery, radiation and chemotherapy although other novel methods, such as 
4immunotherapy are becoming more common.  Choosing the right treatment is based on 
some important factors like the type of cancer, the cancer’s stage, the evidence of 
metastasis, patient age, and the presence of any known genetic mutations.
Surgical treatment is basically where the damaged or diseased organ is removed 
from the body.  This treatment is always for specific organs or locations.  As long as the 
evidence of metastasis is not present after surgery this treatment gives the greatest hope 
of a successful cure.  One of the most important and concerning side effects of surgery is 
formation of a secondary tumor.  In some cases, the eradication of the primary tumor will 
initiate the growth of a metastatic tumor and can help to promote the growth of the 
secondary tumor.
A second type of treatment is to use X- rays (or other high energy radiation) in 
order to destroy the tumor, called radiation therapy.  The theory is that the X- rays target 
the DNA molecules and cause extensive damage to the DNA of the cancer cells, which 
cannot be properly repaired, disrupting cell division and increasing cancer cell death.  
Radiation therapy is used for tumors with a specific location, similar to surgery.  There 
are two types of radiation therapy, external beam radiation therapy and internal radiation 
therapy.  External beam radiation therapy is done by exposing the tumor directly to X-
rays beams.  However, internal radiation therapy is an alternative method of delivering 
radiation and that done by implanting some radioactive pellets or seeds directly on the 
cancer tissue.  The side effects of radiation therapy are general malaise, skin redness, hair 
loss, and mouth sores resulting from damage of adjacent tissues; and, for some women it 
can also cause menopause because of the decreased production of estrogen.  Sometimes 
5radiation-dependent damage to the genetic information in adjacent healthy cells can cause 
oncogenic transformation that will lead to development a new cancer.
Chemotherapy is a commonly used anti-cancer therapy involving the use of 
cytotoxic drugs which have anti-cancer properties and are capable of inhibiting cancer 
cell proliferation or can directly kill these cells.  The mechanism of actions of these drugs 
starts when the cytotoxic agent is delivered through the circulatory system and diffuses to 
the cancer cells and targets the activities of some important molecules in cancer 
progression such as the molecules that are required for cancer cell division (including 
DNA).  The benefit of chemotherapy is that it is focused on systemically killing the 
cancer cells and decreasing their ability to grow independent of the location of the tumor
in the body.   Chemotherapy also decreases the chance of a metastatic tumor forming in 
the future. Chemotherapy, like other therapies, has side effects on the healthy adjacent 
tissue and these effects can be more extensive than radiation therapy. The most 
significant effect of chemotherapy is its ability to kill the fast growing cells of the 
hematopoietic system (blood plus immune system) and gastrointestinal tract.
Other treatments that are also used in treating cancer include biological therapy, 
which is also known as immunotherapy because it is focused on the body’s immune 
system.  This treatment involves using interferon, cytokines, colony- stimulating factors, 
and gene therapy approaches.  Minimizing or eliminating the side effects of cancer 
treatment is an important component in helping to develop improved methods and 
increase the effectiveness of chemoprevention (13). 
61.3. Chemoprevention 
Using natural compounds, synthetic agents, or biological chemical agents in order
to prevent tumor development and formation of metastatic (malignant) tumors is 
commonly known as chemoprevention (14). Chemopreventive agents mainly target the 
carcinogenic process that is driven by specific mutations.  Those mutations can be 
identified in patients early in life, even more than 20 years in advance of metastasis.  The 
mechanisms by which the chemopreventive agents work focuses on blocking mutagenic 
damage to DNA.  Consequently, many of the chemoprevention agents have been 
developed based on their mechanism of action; four classes of new agents were 
developed clinically and experimentally according to their action in the cell.  
Chemoprevention agents are also classified based on their function such as antigenic, 
anti- proliferative, and anti-hormonal agents (16).
The first class of chemoprevention agents was developed based on the 
relationship between inflammation and carcinogenesis to inhibit the function of COX-2 
enzyme activity.  COX- 2 is involved in synthesizing the inflammatory prostaglandins 
produced by arachidonic acid, and the overexpression of the COX-2 gene is linked to 
colon carcinogenesis.  Celecoxib, which is a selective inhibitor of the activity of the 
COX-2 enzyme, is one of these agents.
Selective estrogen receptor modulators (SERMs), such as tamoxifen and 
raloxifene, were developed to prevent prostatic carcinogenesis and tested experimentally 
on rats and shown to work by controlling the binding between the estrogen receptor and 
estrogen analogs.
7Rexinoids (RXRs) are the third important class of chemoprevention agents.  
These agents are able to heterodimerize with retinoic acid receptor (RARs), vitamin D 
receptors, the thyroid receptor, and orphan receptors that are called the nuclear receptor 
superfamily.  The RXRs agents are used in the prevention of mammary carcinogenesis 
and have been evaluated experimentally in rat cancer models.
The last important class of chemoprevention agents is the orphan nuclear receptor,
PPAR-ע, which was developed to prevent colon carcinogenesis because of its high ability 
to bind to fatty acids and prostaglandins (15).   
These chemopreventive components are capable of stimulating programmed cell 
death (apoptosis) in some cancer cells.  Studies have tested their ability to regulate the 
intrinsic or extrinsic apoptotic pathways.  These agents always target the intrinsic 
pathway and control the Bcl- 2 family proteins and inhibit Bcl-2 expression or induce 
Bax expression, to regulate mitochondrial permeability transition (18).
1.4. Natural products and drug discovery 
Natural products have been used as medicines to cure a variety of diseases and 
illnesses for a long time.  In developing countries, the herbal and vitamin medicines are 
still used in primary health care.  In developed countries there is a belief that herbal 
remedies have fewer side effects (19).  Approximately, 71% of the Canadian population 
consumes a natural health product (NPH) (20), such as traditional Chinese medicine, 
traditional Japanese medicine, and traditional Indian medicine (21) and believe these
8medicines to be safe.  The structures of some of the widely used NHPs, including
curcumin and resveratrol are shown in figure 2.
Figure 1.2: The structure of Natural compounds (32)
Apparently, after screening many natural products, antioxidant nutrients and 
phytochemicals were identified which had a low toxicity and were active as anti-oxidant 
chemoprevention drugs (17).  The combination of most phytochemicals with vitamins 
and phenolic agent alkaloids has played a very important role in the discovery of many 
cancer prevention drugs.  These compounds have a role in inhibiting the rapid 
proliferation of cancer cells, inducing apoptosis or promoting differentiation, consistent 
with their chemoprevention properties.  Several may also have antioxidant activities 
which are used as anti-carcinogenesis drugs, specifically for skin carcinogenesis (17).   
Mainly, these natural products are extracted from plants, animals, and microorganisms 
and many of these are found to be effective in treating more than 60 human cancer cell 
9lines, including solid tumors like lung cancer, kidney cancer, prostate cancer, and breast 
cancer (22).
As a result, natural products became the best source for the development of anti-
cancer drugs once they showed the biological activity in screening assay. These materials 
provided the source to identify active chemicals, which were then used as the basis for 
synthesizing of new drugs.  This process is one of the most important processes in 
developing cancer preventive drugs.  Most of the anti-cancer drugs that were originally 
extracted from natural products sources need an accurate analysis of their physiochemical 
features in order to better understand more their anti-cancer activities.  The process of 
discovering an efficient anti-cancer drug started when the natural products extractions 
were purified to identify their active components such as alkaloids (e.g. morphine, 
quinine, and atropine), which are still extensively used (23).
The prior advantages of purifying the active component for the natural extractions
are useful in standardizing the dose amount and for reducing the side effects of these 
ingredients.  In drug discovery processes, these natural product extracts must be tested by 
further biological experiments and by fractionations of these extractions to identify 
further active ingredients, which can then be characterized.  The active components 
identified by this processes can then go through further synthesis by chemists to create 
new, more effective small molecule drugs in order to target diseases based on identifying 
the molecular lesion (23).   Approximately, 119 chemical components isolated from 
plants have been highly used as drugs in many parts of the world (24).
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1.5. Natural products and cancer chemotherapy
Natural products have contributed to the discovery of new drugs used in cancer 
chemotherapy.  This has required a proper understanding of the idiosyncratic mechanisms
of action of the oncology drugs originally derived from natural products in order to 
improve their effectiveness (23).  First, in order to identify any new chemotherapy drug, 
it is important to understand the molecular changes that are involved in the development 
of cancer cells in order to identify target molecules or pathways.  This requires a careful 
study of the genes that are related to cancer and then to identify any specific mutation
which might change activity.  Intelligent drug design requires that the structure of the 
mutant proteins can be determined and modeled to the potential drug.  Optimal structures 
that bind the mutant proteins can then be modeled; this selected molecule can be tested 
experimentally in vitro and in vivo by testing angiogenesis inhibition, signal transduction, 
or activation of protein kinase activity (24).  Some of the anti-cancer effects mediated by
drugs can be based on their mechanism of action.  For example, some anti-cancer drugs 
target the DNA molecules, protein receptors, or enzymes and interfere with normal 
function (23).  
Developing natural products into drugs based on their mechanism of action is a 
relatively new approach to target cancer cells.  For instance, antibody-directed enzyme 
pro-drug therapy is a technique involving the combination of antibody modulated tumor 
targeting and natural products.  The details of this technique involve using specific 
antibodies that bind to an enzyme or other important molecule that accumulates on the 
cancer cell surface.  After a short treatment time, the cells are exposed to a non-cytotoxic 
pro-drug and the enzyme/antibody-binding complex is able to convert the pro-drug to
11
generate the cytotoxic anti-cancer drug at the site of antibody binding.  Therefore, the
anti-cancer drugs are released close to the targeted tumor cells and non-specific cytotoxic 
effects are reduced.  Examples of some of natural product-derived drugs that have been
used in this technique are the Vince alkaloids and Taxols, which were originally, isolated 
from Cephalosporin- alkaloid pro drugs (22). 
1.6. Alkaloids and their effects on cancer 
Alkaloids extracted from some natural products have been shown to have anti-
proliferation and anti-metastasizing activities on many kinds of cancer cells.  
Consequently, alkaloids have provided a rich resource for drug discovery.  For example, 
camptothecin and vinblastine, which have been experimentally developed as anti-cancer 
drugs, were originally isolated as alkaloids from natural sources.  A ring structure and 
nitrogen located in the heterocyclic ring, structurally characterize alkaloids.  The 
alkaloids are classified into different group according to their biosynthetic pathways, such 
as the alkaloids that exist in plants belonging to Ranuuculaceae, Keguminosae, 
Papaveraceae, Menispermaceae, and Loganiaceae (25).
The alkaloids are also diverse based on their biological activities.  For example, 
the action of ephedrine on asthma, the analgesic action of morphine, and the anti- cancer 
effect of vinblastine all have different mechanisms of action.  The typical natural 
alkaloids that show anti-cancer activity are berberine, evodiamine, matrine, piperine, 
sangllinarine, and tetrandrine.  These molecules have been widely studied in terms of 
their anti-cancer activities on many cancer cells and have contributed in the development 
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of  anti-cancer drugs.  Basically, the above alkaloids are isolated from different plant 
families and have different biosynthetic activities and different pharmacological 
activities.  For example, piperine can block some inflammatory activities and mainly has
activity in cancer prevention, whereas other alkaloids, such as berberine are also focused 
on promoting anti-proliferative activity in the cancer cells.  
Figure 1.3: The typical natural alkaloids
The anti-cancer alkaloids have further characteristics that are important in 
understanding their anti-cancer activities (25). First, the alkaloid concentration that 
enhances anti-cancer effects is very important.  For example, the previous alkaloids must 
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be presented to the cancer cells at high concentration compared to other 
chemotherapeutic drugs, such as vinblastine.  On the other hand, marine alkaloids need 
only millimole concentrations to show their anti-cancer activity.  Most of the natural 
alkaloids require structural modification before they are useful as chemotherapy drugs 
because they have low water solubility and poor bioavailability and are a difficulty to get 
to the cancer site.  Finally, the toxicity of these alkaloids must be studied because, like 
other chemicals, they have side effects.  For example, berberin causes side effects 
including anaphylaxis, constipation, and skin allergies and can also cause kernicterus.  
Consequently, the transformation or modification of these alkaloids’ chemical structures 
is required to limit the toxicities of these alkaloids while maintaining their anti-cancer 
activities (25).  
1.7. Natural products as inducers of apoptosis
The mechanism of cell death can be classified into different types which are 
differentiated based on the cellular morphological characteristics and by biochemical and 
cellular parameters.  The main types of cell death that are associated with distinct 
morphological changes are apoptosis, necrosis, and autophagy.  However, the most 
extensively studied are apoptosis and necrosis. 
Necrosis is defined morphologically by an increase in the cell volume, swelling of 
the organelles, fragmenting of the plasma membrane and release of the intracellular 
contents inducing DNA.  Programmed cell death, known as apoptosis, is a controlled 
physiological process to remove the damaged cells.  Apoptosis is characterized by several 
14
structural modifications such as rounding up of the cell, decrease on cellular volume, 
chromatin condensation, DNA fragmentation, and blebbing of the plasma membrane.  
The result is that the cell contents are packaged into membrane-bound vesicles, called 
apoptosomes, which are consumed and degraded by macrophages.  Relatively early 
during the process of apoptosis a group of proteins called caspases, which degrade 
cellules proteins and DNA, are activated.  However, caspase activation is not responsible 
for the execution of cell death (42).
Apoptosis is mainly controlled by two core pathways that are able to induce 
apoptosis, the extrinsic” death receptor” pathway and intrinsic” mitochondrial” pathway.  
The extrinsic pathway is triggered by signals that are activated by binding of ligands to 
death receptors in the plasma membrane.  The intrinsic pathway is regulated at the 
mitochondria and is initiated by the release of cytochrome c to the cytoplasm (figure 4) 
(43).
The natural products show an important role in this field of research because 
some have been shown to induce apoptosis without damaging normal cells.  There are 
plants extracts used as a traditional medicine that are focused on inducing apoptosis in 
abnormal cells.  For example, the aqueous extract of Selaginella tamariscina has been 
shown to increase the expression of the p53 gene and elicit a G1phase cell cycle arrest 
and cause DNA fragmentation in human leukaemia cell lines.  Salanum muriatum
extracts also induced apoptosis by causing DNA fragmentation and PARP cleavage; 
which is one of the apoptosis hallmarks, in prostate cancer (26).
15
Figure 1.4: Apoptosis pathways (47).
The mechanism by which natural chemopreventive agents are found to work is by 
regulating processes related to xenobiotic biotransformation, or by stimulating apoptosis 
in premalignant and malignant cells.  Because, most of these agents target signal 
transduction pathway that regulate apoptosis, understanding how apoptosis is regulated is 
important.  First apoptosis, or a programmed cell death, is a process that causes 
destruction of damaged or abnormal cells (49).
To enhance apoptosis, the chemopreventive agents must target one of the effector 
mechanisms that activate apoptosis.  These effector mechanisms consist of several 
components that correlate with caspase activation or activation of death receptor-
mediated receptors generally known as the extrinsic pathway of apoptosis.  The intrinsic 
Death inducer
16
pathway of apoptosis is mainly focused on mitochondrial mediators such as the Bcl 
family of proteins that disrupt mitochondria function and activate of a caspase cascade 
(49).
The role of most chemopreventive agents is to block or slow cell transformation 
by inducing apoptosis processes.  These agents could also be beneficial for healthy 
people who might be at increased cancer risk.  One concern raised by many researchers is 
that long- term use of these chemopreventive agents might raise the incidence of drug 
resistance for many cancers.  Alternatively, chemoprevention agents may be used only to 
target the tumor cells in patients with cancer by using short-term treatment to enhance 
cellular apoptosis (26). 
The apoptosis process decreases the life span of both normal and cancer cells.  
The aim of most chemotherapy and chemopreventive agents is to preferentially kill 
cancer cells with a lesser effect on normal cells.  Therefore, it is important to screen for 
anti-cancer agents that induce apoptosis in cancer cells to a greater extent than normal 
cells.  
1.8. Uncaria tomentosa (Cat’s claw)
Uncaria tomentosa is a woody vine, in the Rubiaceae family (30), commonly 
known as Cat’s Claw (27).  It was originally found in the Amazon rainforest and in 
various areas of South and Central America (30).  The native Indians used Uncaria 
tomentosa as a tea made from its bark or roots (28) which are the most commonly used 
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parts of Uncaria tomentosa (29).  It has been more recently found that the organic 
components of Uncaria tomentosa have cytotoxic and anti-inflammatory activities (28), 
and that the Uncaria tomentosa bark is rich in alkaloids, quinovic acid, glycosides, and 
phenolic compounds (29) which have been used medicinally to treat several diseases such 
as inflammation, rheumatism, arthritis, and cancer (31).
Several studies have shown the anti- inflammatory activity of Uncaria tomentosa
in vivo and in vitro and have identified a role for Uncaria tomentosa in inhibiting tumor 
initiation and growth.  Uncaria tomentosa is one of the anti- inflammatory drugs that has 
been shown to possess effective action in cancer therapy and prevention. Uncaria 
tomentosa was shown to inhibit NF-κB, which is an important transcription factor in both
chronic inflammation and cancer and it is an important target in cancer therapy (32).
Different preparations of Uncaria tomentosa have been found to have different
anti- inflammatory activities such as reducing the production of the inflammatory 
cytokine TNFα.  Also, it has a role in eliciting the production of factors that control 
lymphocyte- proliferation by human endothelial cells.  Uncaria tomentosa extracts have 
also been shown to have the ability to enhance DNA repair and protect lymphocytes from 
apoptosis (34).
Recently, many studies have determined the biological activities of Uncaria 
tomentosa. These studies have found that these activities are mediated by the presence of 
different effective components such as tetracyclic and pentacyclic oxindole alkaloids.  In 
addition, phenolic components such as flavonoids and phenolic acids were shown to be 
responsible for the high antioxidant activity (33).
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Chapter 2:  Thesis objectives
The objectives of this thesis are to:
1- Study the effect of Uncaria Tomentosa on the melanoma cell line, B16-BL6.
2- Determine the mechanism of action of Uncaria Tomentosa in promoting cancer 
cell death.
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Chapter 3:  Materials and Methods
3.1. Tissue culture
The B16-BL6 (murine melanoma), HEK293T( human embryonic kidney cells) 
and HSG ( human salivary gland) cell lines were obtained from ATCC [American Type 
Culture Collection, Manassas, VA] and maintained in Dulbecco’s Modified Essential 
Medium (DMEM, Hyclone, Logan, UT) supplemented with 10% fetal bovine serum 
(Hyclone), 100 µg/ml streptomycin, and 100 U/ml penicillin (Invitrogen, Burlington, 
ON).  Cells were incubated at 37 ºC in 5% CO₂.  For experiments, the cells were treated 
with media containing Uncaria tomentosa or the individual component at various 
concentrations as indicated.  All experiments were run in triplicate and data were 
analyzed from three independent experiments. 
3.2. Extracts of Uncaria tomentosa
Uncaria tomentosa was provided as a dried powder of the roots by Rosa Rosales
(Lima, Peru) or purchased as a NHP (Cat's Claw extract, Now Foods, Bloomington, IL. 
code 84618).  The powder was extracted with either water or 70% ethanol and the soluble 
fraction used in experiments.  Equivalent results were obtained for the Uncaria 
tomentosa acquired from both sources.  For the aqueous extraction, 1 g of Uncaria 
tomentosa powder was suspended in 10 ml water and boiled for 1h.  For the ethanolic 
extraction, 1g of Uncaria tomentosa powder was suspended in 10 ml 70% ethanol and 
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boiled for 1h. The insoluble material was removed by centrifugation at 10,000 x g for 10 
min and then the supernatant filtered through a 0.22 m syringe filter.
For some experiments the Uncaria tomentosa was fractionated over an ethanol-
water gradient.  Fifty grams of Uncaria tomentasa powder was suspended and boiled in 
500 ml of 70% ethanol for 1 h.  The mixture was filtered to through 1mm Whatman filter 
paper and the filtrate freeze-dried (a sample of dried powder was removed).  The Uncaria 
tomentosa extract was then resuspended in 200 ml water and mixed with 20 g of 
poly(vinylpolypyrrolidone) matrix (Sigma Chemical, St Louis, MO).  The mixture was 
poured into a column and 50 ml fractions taken.  The column was sequentially eluted 
with 200 ml each of water, 20% ethanol, 40% ethanol, 60% ethanol, 80% ethanol, and 
100% ethanol. The fractions were either freeze-dried or evaporated to a powder for use in 
cell growth and HPLC experiments.
3.3. Cell treatments
The B16-BL6, HEK 293T, and HSG cells, cultured and maintained in DMEM
containing 10% fetal calf serum, were treated with Uncaria tomentosa extracts at various 
concentrations and allowed to grow in 5% CO2 at 37ºC.  For treatments, the cells were 
collected by centrifugation at 1000xg and plated onto 96 well plates at approximately 
20% confluence (2000 cells/well).  Two different preparations of Uncaria tomentosa
were used; the aqueous extract (1000 mg/ml) and the ethanolic extract (1000 mg/ml).  
The two extracts were compared by HPLC in order to ensure equivalent quantities of the 
detected components.  The two extracts were resuspended in DMEM media before 
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treatment.  For treatments, different doses of these stock solutions were applied to the cell 
cultures.  For each experiment, water and ethanol were used at the same dose to generate
negative controls.
3.4. MTT assay (Methyl Tetrazolium Blue)
B16-BL6, HEK293T, and HSG cells were plated on 96-well plates at a 
concentration at approximately 2x10ᶟ cells per well & incubated for 24 hours (5% CO₂
37°C).  Cells were treated with 0.01% (low dose) or 1% (high dose) Uncaria tomentosa
extract in media on day 0; media alone served as a negative control.  Cells were treated 
for varying times (1-5 days) without a media change.  Cell viability was measured daily 
using the MTT assay.  To each well, 10 µl/ml of 0.25 mg/ml MTT was added followed 
by a 4 hour incubation.  The media was removed and 100 µl DMSO was added to 
solubilize the crystals.  Absorbance at 450 nm was measured on a plate reader
(Spectramax 340PC 389).
3.5. Wound healing migration assay
Cells were plated on 6 well plates at an approximate confluence of 1x10⁶
cells/well and cultured overnight in media.  Wounds were made in the confluent
monolayers using a 200 µl plastic pipet tip.  Cells were treated with culture media in the 
presence of 0.01 or 1% Uncaria tomentosa extract. Digital photographs of the wounds 
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were taken (using an Axiovert 100 microscope) at 0 h, 6 h, 12 h, 24 h, 48 h, and 72 h post 
treatment and changes in the distant spanned by the wounds were measured.
3.6. Acridine orange and ethidium bromide staining
B16-BL6 cells were plated on glass cover slips in culture media overnight at 37◦C 
to allow the cells to adhere.  Cells were treated with Uncaria tomentosa extract (0.01% 
low dose or 1% high dose) on day 0.  B16-BL6 cells treated with 6 μg/ml of 
camptothecin as a positive control for apoptosis.  Cells were treated for 6 h, 12 h, 24 h, 48
h, or 72 h.  Cells were stained with 100 g/ml acridine orange (Sigma-Aldrich) for 5 min 
and then stained with 100 g/ml of ethidium bromide (Sigma-Aldrich) for 5 min.  
Coverslips were washed in PBS, gently mounted onto a glass slide, and sealed with clear 
nail polish.  Fluorescence was visualized using an LSM510 microscope.
3.7. TUNEL assay of DNA fragmentation
B16-BL6 cells were plated on glass cover slips overnight at 37◦C to allow the 
cells to adhere.  Cells were treated with Uncaria tomentosa extract (0.01% low dose or 
1% high dose) on day 0 and incubated for 72h.  B16-BL6 cells treated with 6 μg/ml of 
camptothecin were used as a positive control for apoptosis. Cells were fixed with 4% 
paraformaldehyde (freshly prepared) for 5 min.  Cells were then permeabilized by 
incubation with 0.1% TritonX-100 in 0.1% sodium citrate (freshly prepared) for 2 min on 
ice.  The cell cultures were washed with PBS and treated with in 50 µl/well TUNEL 
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reaction mixture (Roche, Laval, QB).  The reaction was incubated for 60 min at 37°C in a 
humidified atmosphere in the dark.  The cells were washed twice in PBS, pH 7.4, and 
then the cover slips were transferred to glass slides.  Samples were directly analyzed 
using a fluorescence microscope.
3.8. Flow cytometry
B16-BL6 cells grown in 60 x 15 mm tissue culture plates.  The cells were treated 
with Uncaria tomentosa at 0.01% for the low concentration, 0.1 % for medium and 1 
µl/ml for high concentration.  B16-BL6 cells treated with 6 μg/ml camptothecin as a 
positive control for the detection of apoptosis.  The cells were then washed with PBS, 
harvested by incubation in 0.25% (w/v) trypsin-EDTA and then collected by 
centrifugation at 400 x g for 10 min.  The cells were fixed by adding cold 70% ethanol 
and incubated at -20ºC.  The cells were then subjected to centrifugation at 400 x g for 10 
min and washed twice with PBS.  The cells were re-suspended in 500 μl of propidium 
iodide (PI) staining solution (165 mM NaCl, 10% Triton 100, 50 μg/μl RNase A, 200 
μg/ml of propidium iodide).  Samples were analyzed on a Beckman Coulter LS600 flow 
cytometer.
3.9. Western blot analysis
Cell monolayers were cultured on 100 mm2 plates and treated with Uncaria 
tomentosa extracts for 1-3 days.  The cells were collected in RIPA (0.5% SDS, 0.5% 
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sodium deoxycholate, 1% Triton X-100, 150 mM sodium chloride, and 250 mM Tris-
HCl, pH 7.4) and lysed.  Protein concentrations were determined using a BCA assay and 
25 µg of cell lysate was separated by on a 10% polyacrylamide gel containing SDS
(SDS-PAGE).  Proteins were transferred to a nitrocellulose membrane (Whatman, 
Mandel Sci., Burlington, ON) using a BioRad semi-dry transfer machine.  Blots were 
stained with 0.5% Ponceau S in 1% acetic acid to confirm uniform loading.  The 
membranes were blocked by incubation in blocking buffer containing 20 mM Tris-HCl, 
pH 7.4, 150 mM sodium chlordie, 0.05% Tween-20 (TBST) and 5% bovine serum 
albumin (BSA, Sigma).  After washing with TBST, the membranes were incubated in 
anti-caspase-3 mouse antibody (Cell Signaling Inc, Lake Placid, NY, titre 1:1000).  The 
blots were washed and incubated with an appropriate secondary antibody (goat anti-
mouse IgG- HRP) (Santa Cruz Biotechnology, Santa Cruz, CA; titre 1: 10,000) for 1 hour 
and then washed twice with TBST and once with TBS.  The blots were then incubated for
5 min in enhanced chemiluminescence reagent (ECL, Pierce Chemical Co., Toronto, ON)
and then exposed to X-ray film.
3.10. HPLC (High-performance liquid chromatography)
Uncaria tomentosa extracts were fractionated on poly (vinylpolypyrollidone)
columns into different fractions starting by the aqueous fraction, 20% ethanol, 40% 
ethanol, 60% ethanol, 80% ethanol, and 100% ethanol.  The alkaloid composition of 
these fractions was determined by using High-performance liquid chromatography 
(HPLC) on a Breeze 2 chromatography system (Waters Inc, Toronto, ON).  Each fraction 
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was separated by using a Sunfire C18 column 3.5 μm resin 4.6x100 mm.  The solvents 
used were; (A) 60 volumes 10 mM phosphate buffer, pH 6.6, 20 volumes acetonitrile, 
and 20 volumes methanol, and (B) 30 volumes 10 mM phosphate buffer, pH 6.6, 35 
volumes acetonitrile, and 25 volumes methanol.  Solvent was pumped through the 
column at 1ml/min.  First, the solvents were mixed using a gradient starting with 100% 
buffer A and finishing with 100% B over a time period of 40 min.  Then, 100% buffer B 
was pumped through the column for 10 min and finally a gradient starting with 100% B 
and finishing with 100% was pumped through the column for 5 min.  The components in 
the Uncaria tomentosa extract were detected using a wavelength of 245 nm and the 
detected peaks compared to a group of standards (Planta Analytical).
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Chapter 4:  Results
4.1. Inhibition of B16- BL6 cell proliferation treated with Uncaria tomentosa
The effect of Uncaria tomentosa treatment on the growth of B16- BL6 cell 
cultures was determined.  B16-BL6 treated with two different extracts (water and 70% 
ethanol) of Uncaria tomentosa showed significant inhibition of proliferation.  The 
number of cells in cultures treated with Uncaria tomntosa was significantly reduced at 
day 3 in a dose-dependent manner.  The number of cells in high dose (1%)-treated 
cultures was approximately 50% of the suspending media control (Figures 4.1 and 4.2).  
B16-BL6 cell proliferation was consistently reduced for at least 5 days after the 
treatment.  At the highest doses, the number of cells did not increase compared to day 0.
Treatment of the non-malignant cell lines, HEK293 and HSG cells, with extracts 
of Uncaria tomentosa also significantly inhibited cell proliferation in a dose-dependent 
manner (Figures 4.3, 4.4. 4.5, and 4.6).  In all cases, treatment with the ethanolic extract 
was more effective in inhibiting cell proliferation than was the aqueous extract.  In 
addition, there were some differences in the sensitivity of the cell lines to Uncaria 
tomentosa.  The HSG cells were much less sensitive to the aqueous extract compared to 
HEK293T and B16-BL6 cells although all three cell lines showed similar sensitivity to 
the ethanolic extract (Figure 4.7).
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Figure 4.1: Effect of the ethanolic extract of Uncaria tomentosa on B16- BL6 cell
growth.
B16- BL6 cells were treated with different concentrations of Uncaria tomentosa 
extracted with 70% ethanol (0.01, 0.05, 0.1, 0.5, and 1% Uncaria tomentosa in media).   
Cell proliferation was measured using the MTT assay.  The cells were incubated with the 
Uncaria tomentosa extract for five days and absorbance was determined each day.  Data 
were analyzed for three independent experiments. 
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Figure 4.2: Effect of the aqueous extract of Uncaria tomentosa on B16-BL6 cell 
growth.
B16- Bl6 cells were treated with different concentrations of Uncaria tomentosa extracted 
with water (0.01, 0.05, 0.1, 0.5, and 1% Uncaria tomentosa in media).   Cell proliferation 
was measured using the MTT assay.  The cells were incubated with the Uncaria 
tomentosa extract for five days and absorbance was determined each day.  Data were 
analyzed for three independent experiments. 
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Figure 4.3:  Effect of ethanol extracts of Uncaria tomentosa on non-malignant 
HEK293Tcell growth.
HEK293T cells were treated with different concentrations of Uncaria tomentosa
extracted with 70% ethanol (0.01, 0.05, 0.1, 0.5, and 1% Uncaria tomentosa in media).   
Cell proliferation was measured using the MTT assay.  The cells were incubated with the 
Uncaria tomentosa extract for five days and absorbance was determined each day.  The 
graphs represent one of at least three independent experiments.
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Figure 4.4:  Effect of aqueous extracts of Uncaria tomentosa on non-malignant 
HEK293Tcell growth.
HEK293T cells were treated with different concentrations of Uncaria tomentosa
extracted with water (0.01, 0.05, 0.1, 0.5, and 1% Uncaria tomentosa in media).   Cell 
proliferation was measured using the MTT assay.  The cells were incubated with the 
Uncaria tomentosa extract for five days and absorbance was determined each day.  The 
graphs represent one of at least three independent experiments.
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Figure 4.5:  Effect of ethanol extracts of Uncaria tomentosa on non-malignant HSG 
cell growth.
HSG cells were treated with different concentrations of Uncaria tomentosa extracted 
with 70% ethanol (0.01, 0.05, 0.1, 0.5, and 1% Uncaria tomentosa in media).   Cell 
proliferation was measured using the MTT assay.  The cells were incubated with the 
Uncaria tomentosa extract for five days and absorbance was determined each day.  The 
graphs represent one of at least three independent experiments.
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Figure 4.6:  Effect of aqueous extracts of Uncaria tomentosa on non-malignant HSG 
cell growth.
HSG cells were treated with different concentrations of Uncaria tomentosa extracted 
with water (0.01, 0.05, 0.1, 0.5, and 1% Uncaria tomentosa in media).   Cell proliferation 
was measured using the MTT assay.  The cells were incubated with the Uncaria 
tomentosa extract for five days and absorbance was determined each day.  The graphs
represent one of at least three independent experiments.
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Figure 4.7: Comparison of the effect of Uncaria tomentosa extract on multiple cell 
lines.
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To show the stability of the active agents in the extracts, we stored the different 
extracts of Uncaria tomentosa at 4o C for four weeks.  Each week, the effect of the 
extracts on the proliferation of B16- BL6 cells was tested.  The results of these studies
showed that the Uncaria tomentosa extracts were stable and promoted a similar level of 
cell growth inhibition for at least four weeks (Figures 4.8. and 4.9.). 
4.2. Treatment with Uncaria tomentosa inhibits cell migration
The effect of the Uncaria tomentosa on B16- BL6 migration was determined by 
using a wound healing migration assay.  Cells treated with both extracts of Uncaria 
tomentosa showed a significant inhibition in the cell migration especially in the high 
concentration of the ethanolic extract of Uncaria tomentosa during different time points 
starting from 0 h and extending until 72 h after treatment (Figure 4.10 and 4.11.).
Treatment with the aqueous extract was less effective and the diameter of the wound was 
reduced to approximately 50% within 72 h. Treatment with the positive control, 
camptothecin, almost completely inhibited cell migration while cells treated only with 
suspending media completely closed the “wound” within 24 h.
4.3. Uncaria tomentosa effects B16-BL6 morphology
B16-BL6 cells treated with both extracts of Uncaria tomentosa for 72 h showed a 
significant change in the cell morphology.  The treated cells showed an elongated and 
stellate morphology especially in the cells treated with the high concentration of the 
ethanol extract (Figure 4.12.)
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Figure 4.8: Stability of the Uncaria tomentosa extracts (2 weeks).
Uncaria tomentosa was extracted in 70% ethanol and these stored at 4 C.  Each week, the 
effect of the extract on the proliferation of B16-BL6 cells was treated as described in 
Figure 4.1.
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Figure 4.9: Stability of the Uncaria tomentosa extracts (4 weeks).
Uncaria tomentosa was extracted in 70% ethanol and these stored at 4 C.  Each week, the 
effect of the extract on the proliferation of B16-BL6 cells was treated as described in 
Figure 4.1.
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Figure 4.10: Effect of Uncaria tomentosa on the migration of B16-BL6 cells.
The effect of Uncaria tomentosa on B16-BL6 migration was determined by using wound 
healing migration assay.  A 200 μl yellow pipet tips was used to score a wound in the 
monolayer (width = 45 mm).  The cells were then incubated with various doses of 
Uncaria tomentosa and the width of the wound measured at various time of incubation.  
Cells were treated with low dose (0.01%) and high dose (1 %) of the two extracts of 
Uncaria tomentosa.  Cells were treated with a positive control of Camptothecin and a 
media negative control.  Digital photographs of the wounds were taken at 0 h, 6 h, 12 h, 
24 h, 48 h, and 72 h post-treatment. The treatment with a high concentration of the 
ethanolic extract showed an inhibition on cell migration.  The experiment was done three 
times.  
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Figure 4.11: Effect of Uncaria tomentosa on the migration of B16-BL6 cells.
A graphical presentation of the effect of the Uncaria tomentosa extracts on B16-BL6 
migration as determined by using wound healing migration assay described in Figure 
4.10.  The experiment was done three times.  
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Figure 4.12:  Changes in B16-BL6 morphology caused by Uncaria tomentosa
treatment.
B16-BL6 cells were treated with low dose (0.01%) and high dose (1 %) of Uncaria 
tomentosa extract and incubated for three days before pictures were taken.  Uncaria 
tomentosa treated B16- BL6 cells showed a decrease in number and a slight change in 
morphology.  The experiment was done three times.
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4.4. Treatment with Uncaria tomentosa effects cell DNA content
The effect of the Uncaria tomentosa extract on B16-BL6 cell cycle distribution was 
determined by using flow cytometry.  A propidium iodine staining solution was used to 
measure the amount of DNA in each cell.  The number of cells with DNA content less 
than normal G1 cells (the sub-G1 population) was increased in cells treated with extracts 
of Uncaria tomentosa in a dose-dependent manner (Figure 4.13).  The presence of cells 
in the sub-G1 peak is a marker of an apoptotic cell population.  Cells treated with the 
ethanolic extract of Uncaria tomentosa showed a significant increase in sub-G1 cells 
which increased to over 70% of the cells following treatment for 72h. The aqueous 
extract was less active and showed an increase to 10% of the cells in the sub-G1 peak 
after 72 h.   Treatment with camptothecine for 24 h increased the sub-G1 population to 
approximately 25%.  It is of some interest to note that cells treated with lower 
concentrations of Uncaria tomentosa extracts for 72 h still showed a small G2 DNA peak 
(approximately 50% the proportion of cells in media controls) which suggests that 
individual cells were still able to go through the cell cycle.  
4.5. Treatment with Uncaria tomentosa induces apoptosis
To examine the ability of the ethanolic extract of Uncaria tomentosa treatment to 
induce apoptosis in B16- BL6 cells, a cell staining assay (Acridine orange/ Ethidium 
bromide) was used.  Treatment of B16-BL6 cells with the ethanolic extract of Uncaria 
tomentosa showed morphological changes, such as membrane blebbing and chromatin 
condensation as visualized by fluorescence microscopy (Figures 4.14 and 4.15).
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Figure 4.13: The effect of Uncaria tomentosa on cell cycle profiles (sub-G1 peaks).
The effect of Uncaria tomentosa on DNA content was determined by flow cytometry.  
B16-BL6 were treated with both extracts of Uncaria tomentosa at various concentrations
(0.01%, 0.1%, and 1%) or treated with 6 µg/ml camptothecin as a positive control.  Cells 
were collected after three days of treatment and incubated with propidium iodide staining
solution for 60 min.  The samples were analyzed on a Beckman-Coulter LS600 flow 
cytometer.  The percentage of cells in the Sub-G1 (apoptotic cells) peak is shown on the 
histogram. 
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Figure 4.14: Detection of apoptosis in B16-BL6 cells using acridine orange and 
ethidium bromide staining.
Cells were cultured on glass coverslips and treated with different concentrations (0.01%
and 1%) of both extracts of Uncaria tomentosa.  Cells were treated with campothecine as 
a positive control to detect apoptosis and with media as the negative control.  Cells were 
stained by incubation in a mixture of 100 µg/ml acridine orange and 100 µl/ml ethidium 
bromide for 10 min.  The morphological changes in the apoptotic cells were visualized by 
using an LSM510 microscope.  Uncaria tomentosa appears to cause apoptosis at high 
concentration.  The experiment was done three times. 
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Figure 4.15: Detection of apoptosis in B16-BL6 cells using acridine orange and 
ethidium bromide staining.
Cells were cultured on glass coverslips and treated with different concentrations (0.01% 
and 1%) of both extracts of Uncaria tomentosa.  Cells were treated with campothecin as a 
positive control to detect apoptosis and with media as the negative control.  Cells were 
stained by incubation in a mixture of 100 µg/ml acridine orange and 100 µg /ml ethidium 
bromide for 10 min.  The morphological changes of the apoptotic cells were visualized 
by using an LSM510 microscope.  Uncaria tomentosa appears to cause apoptosis at high 
concentration.  The experiment was done three times. 
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The TUNEL assay was also used to identify DNA fragmentation induced by 
Uncaria tomentosa treatment, which is another hallmark of apoptosis.  B16-BL6 were 
treated with the ethanolic extract of Unacaria tomentosa for 72 h and then stained with 
terminal transferase by the TUNEL reaction.  The nuclear staining was visualized by 
fluorescence microscopy.  The results showed that cells treated with the ethanolic extract 
of Uncaria tomentosa induced DNA fragmentation in treated cells after 3 days (Figures 
4.16. and 4.17).  Treatment with the aqueous extract of Uncaria tomentosa was not as 
effective at inducing DNA fragmentation.  This is consistent with the results from the 
flow cytometry and acridine orange/ ethidium bromide staining results.  This supports the 
idea that treatment of cells with Uncaria tomentosa extracts induces apoptosis which 
decreases the growth of treated cell cultures.
4.6. Treatment with Uncaria tomentosa causes caspase-3 cleavage
Since these results have supported the idea that the treatment with the ethanolic 
extract of Uncaria tomentosa induced apoptosis, we further examined the effect of 
treatment with the ethanolic extract of Uncaria tomentosa on caspase-3 cleavage.  
Caspaxe-3 cleavage is a classic indicator of apoptosis.  Cells treated with the ethanolic 
extraction of Uncaria tomentosa showed caspase-3 cleavages after 72 h treatment 
compared to the positive control (camptothecin), providing further evidence that the 
Uncaria tomentosa mechanism of action to kill cells is by apoptosis (Figure 4.18.).
Treatment of cells with the aqueous extract of Uncaria tomentosa showed a very weak 
band corresponding to the cleaved form of caspase-3, consistent with the previous results.
60
Figure 4.16: Detection of DNA fragmentation in B16-BL6 cells treated with Uncaria 
tomentosa using TUNEL assay (0 h).
Detection of DNA fragmentation after treatment with Uncaria tomentosa was done by 
using the Terminal deoxynucleotidyl transferase (TUNEL) assay.  Cells were plated on 
glass coverslips and treated with different concentrations (0.01% and 1%) of Uncaria 
tomentosa extracts.  Cells were treated with campothecin as a positive control and with 
culture media as a negative control.  At 0 h of treatment, the cells were incubated with 50 
µl of TUNEL reaction mixture for 60 min at 37 C° in the dark. The samples were 
analyzed using a fluorescence microscope to detect labelled cell nuclei.  Uncaria 
tomentosa does not cause DNA fragmentation at time 0 h.
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Figure 4.17: Detection of DNA fragmentation in B16-BL6 cells treated with Uncaria 
tomentosa using the TUNEL assay (72 h).
Detection of DNA fragmentation after treatment with Uncaria tomentosa was done by 
using the Terminal deoxynucleotidyl transferase (TUNEL) assay.  Cells were plated on 
glass coverslips and treated with different concentrations (0.01% and 1%) of Uncaria 
tomentosa extracts.  Cells were treated with campothecin as a positive control and with 
culture media as a negative control.  At 72 h of treatment, the cells were incubated with 
50 µl of TUNEL reaction mixture for 60 min at 37 C° in the dark.  The samples were 
analyzed under a fluorescence microscope to detect labelled cell nuclei.  Uncaria 
tomentosa appears to cause DNA fragmentation in the high concentration of ethanolic 
extract after three days of treatment.
63
64
Figure 4.18: Effect of Uncaria tomentosa treatment of B16-BL6 cells on caspase-3 
cleavage.
The effect of Uncaria tomentosa on apoptosis was determined by using western blot 
analysis and by analyzing Caspase cleavage.  Cells were treated with two extracts of 
Uncaria tomentosa at different concentrations (0.01%, 0.1%, and 1%) and treated with 6
µg/ml camptotecin as a positive control and media as negative control.  The cells lysates 
were electrophoresed on a 15% polyacrylamide gel and then transferred onto a 
nitrocellulose membrane.  The membrane was incubated with primary antibody (anti-
Caspase-3) followed by incubation with a secondary antibody.  The treatment with 
Uncaria tomentosa especially the ethanolic extraction showed Caspase-3 cleavage. 
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4.7. Identifying the major components of the Uncaria tomentosa extracts
Uncaria tomentosa extractions fractions were analyzed by using HPLC in order to 
identify the major components.  Uncaria tomentosa fractions were subjected to HPLC 
and the chromatographs (Figure 4.19.) showed several peaks which appear similar in 
both the ethanol and aqueous extracts.  Several of these peaks correspond to the known 
standard alkaloid components of Uncaria tomentosa; uncarine C, uncarine D, uncarine E, 
mitraphylline, isomitraphylline, and rhynophylline although a few unidentified peaks are 
also seen.  Separation of the ethanolic extract of Uncaria tomentosa on an ethanol 
gradient also showed the ability to separate the various alkaloids.  The pure aqueous 
fraction (H2O), and 20% ethanol fractions showed similar patterns of alkaloids compared 
to the parent ethanol extract (Figure 4.20.).  The 40 % ethanol and 60% ethanol fractions 
showed a significant decrease in the amount of alkaloid detected and showed a change in 
the proportions of the various standard compounds that were present.  The 80% and 
100% ethanol fractions showed very low levels of alkaloids.  The ability of the ethanol 
gradients to separate out some of the components of the Uncaria tomentosa extracts 
suggests that this method might be useful in identifying the active components that affect 
cell apoptosis in future experiments.
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Figure 4.19: HPLC analysis of Uncaria tomentosa extracts.
Uncaria tomentosa extracts were analyzed by using HPLC to characterize the major 
components.   Uncaria tomentosa powder was extracted in water or 70% ethanol 
solutions and freeze-dried. The resulting powder was resuspended in 50% ethanol at 50 
mg/ml and subjected to the HPLC.  The spectra show the relative position of several 
standard alkaloids fractionated under the same conditions. The identification of some 
additional peaks will be investigated further.
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Figure 4.20: HPLC analysis of fractionated Uncaria tomentosa extracts
Uncaria tomentosa powder was extracted in 70% ethanol and then fractionated into 
different fractions using an ethanol gradient.  The various fractions were analyzed using 
the HPLC in order to identify the major ingredients.  The HPLC analysis of the Uncaria
tomentosa fractions showed several alkaloid peaks in water, and 20% ethanol fractions 
which decreased in amount in the 40 % ethanol and 60% ethanol fractions.  The 
identification of those peaks will be under investigation in the future.
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Chapter 5:  Discussion
The results of these studies showed that treatment with Uncaria tomentosa
inhibited the proliferation of the murine melanoma cell line B16-BL6.  However, the
Uncaria tomentosa extract showed a similar effect on non-malignant cell lines in 
reducing cell growth.  Thus, indicating that Uncaria tomentosa is an unselective drug 
because of it can inhibit the growth of cells that reproduce rapidly whether they are 
malignant or non-malignant.  Moreover, treatment with Uncaria tomentosa was shown to 
stimulate programmed cell death (apoptosis) in cancer cells.
Most of the natural products that have been shown to have medicinal value have 
an inhibitory effect on cell proliferation and hormone metabolism; or can induce cell 
differentiation (35).  Consequently, natural products such as green tea, garlic, and 
curcumin can be developed into chemoprevention agents because it is believed that these 
products are mostly non-toxic and show an inhibitory effect on carcinogenesis in rodents 
(36).  
In order to identify the effectiveness and the mode of action of these medicinal 
plants, some biological experiments in vivo and in vitro must be done.  Uncaria 
tomentosa, or“ cat’s claw”, has been shown to have anti-cancer and anti- inflammatory 
activities, which are the most important activities required for treating different diseases 
such as gastric illnesses, arthritis, rheumatism, and cancer (37).
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Several studies confirm that Uncaria tomentosa has some effects on the treatment 
of these disorders.  Akesson’s study reported that Uncaria tomentosa bark is capable of 
inhibiting the growth of several cancer cell lines (38).  Further, results from this study 
showed that Uncaria tomentosa reduced cancer cell proliferation in a dose-dependent 
manner compared to the control cultures.   Moreover, this result was observed in several 
malignant and non-malignant cell lines.  They concluded their study by suggesting that 
Uncaria tomentosa can control cell growth and cell cycle progression (38).  
5.1. Anti-proliferation activity of Uncaria tomentosa extracts
The anti-proliferative properties of Uncaria tomentosa have been confirmed by 
many studies.  Fazio’s study reported the inhibition of cancer cell proliferation follows 
treatment for 24h and that inhibition was less than 50% among the different tumor cell 
lines that were used in his study (36).  Otherwise, Uncaria tomentosa's anti- proliferative 
activity has been demonstrated in immune cells such as THP-1 monocytes.  However,
THP-1 monocytes treated with Uncaria tomentosa extracts did not show any increase in 
the proportion of dead cells (37).
In our study, we tested two different preparations of Uncaria tomentosa; the 
ethanolic and water extracts, for their anti- proliferation activities.  The ethanolic extract 
was prepared by using 70% ethanol as the extraction solvent.  These extractions were 
mainly tested in the murine melanoma cell line (B16-BL6) and in some other non-
malignant cell lines (HSG and HEK923T). In order to demonstrate the bioactivity of 
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these extracts, they were tested at different concentrations started from the lower (0.01%) 
to the higher concentrations (1%) (38).
The proliferation rates of the cells were measured using the Methyl-tetrazolium 
assay (MTT) (39).  The main principal of the MTT assay is counting the total number of 
the viable cells that have active mitochondria.  The MTT solvent is induced by these 
active mitochondria to produce formazan products.  The ability of the cytotoxicity drugs 
to inhibit cell proliferation is varied between the cell lines according to the results from 
these experiments (40).  The various results showed different activity between the two 
types of extracts and between different cell lines (41).  The Uncaria tomentosa extracts 
added to the different cancer cell lines also showed a significant decrease in cell 
proliferation.  This is an expected activity of the Uncaria extracts as an anti-proliferative 
drug in cancer cells as described previously (39).
Both of the extracts were made by suspending 0.1 g/ml of Uncaria tomentosa
bark powder in either water or 70% ethanol.  When the extract was dried, approximately 
50% of the original weight was recovered.  When added to the cells at a concentration of 
1% (the higher concentration) both extracts showed a significant decrease in the growth 
for malignant and non-malignant cell lines.  However, at concentrations of 0.01- 0.1% of 
Uncaria tomentosa, extracts showed lower levels of inhibition in cell proliferation in all 
tested cell lines.  According to this result, ethanol extracts of Uncaria tomentosa had the 
greatest anti-proliferative activity.  The concentration of 1% Uncaria tomentosa extracts 
significantly inhibited the proliferation of B16- BL6, HEK-293T and slightly inhibited 
HSG cell proliferation.
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Additional assays were done to prove the effects of the Uncaria tomentosa
extracts on the growth and movement of the cells from one area to another.  This assay is 
the wound healing migration assay and it confirmed that the ethanol extract of Uncaria 
tomentosa showed a significant effect in reducing the migration of the cells from one area 
to another.
5.2. Dose and time dependency of Uncaria tomentosa
The activity of Uncaria tomentosa in inhibiting cancer metastasis to the lung by 
the murine melanoma cell line B16-BL6 had been shown in mice.  The mice were 
inoculated with B16-BL6 cells via the tail vein and then injected with 50 μg of Uncaria 
tomentosa daily for 20 days.  Consequently, the size of the lung tumors found in the mice 
treated with 50 μg of Uncaria tomentosa was significantly inhibited; notably, treated 
tumors measured approximately 75% less than the control up to day 16 (36).
In our study, the results showed a dose-dependent inhibition of growth for the 
murine melanoma cell line B16-BL6 in vitro.  The low doses of Uncaria tomentosa
showed a range of growth inhibition of between 10% to 30% fewer cells.  However, more 
than a 50% reduction in the number of cells was seen when the cultures were treated with 
the high dose of Uncaria tomentosa for 48 h treatment.  These data support the idea that 
there is an effective anti-cancer component in Uncaria tomentosa. 
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5.3. Apoptosis induction by Uncaria tomentosa
Natural products have been found that are able to regulate cell death by eliciting 
or inhibiting apoptosis.  The aim of studying the effect of natural components on 
apoptosis is to identify and improve the critical apoptotic component that is capable of 
inducing programmed cell death in cancer cells.  Consequently, examining these 
compounds may help to discover a new anti-cancer drug.  Many studies support the 
ability of natural products to control both the intrinsic and extrinsic apoptosis pathways 
and our experimental results showed that Uncaria tomentosa could induce and control 
apoptosis.
To identify the mechanism of action of Uncaria tomentosa and whether it is an 
apoptosis inducer or not, several experiments were done to identify any morphological 
and biochemical modifications.  To determine the morphological changes, the cell were 
stained with a combination of acridine orange and ethidium bromide. Acridine orange is 
capable of staining both live and dead cells and they appear green under the microscope.  
The nuclei morphology is visible in the stained cells and nuclear condensation or 
fragmentation can be detected.  However, ethidium bromide stains only the dead cells 
that have lost membrane integrity and are a good indicator of necrosis or late apoptosis in 
cells treated for many days (44). Therefore, the cell staining assay is one of the apoptosis 
assays that shows the nuclear changes due to chromatin condensation and DNA 
fragmentation (44).
In both extracts, the cells showed chromatin condensation after three days 
treatment.  However, treatment with the ethanolic extract of Uncaria tomentosa caused 
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the cells to show membrane blebbing early on and chromatin condensation was present
by 48 h treatment.  In contrast, treatment with the aqueous extract did not show early 
membrane blebbing and chromatin condensation was not evident until 72 h of treatment.  
This shows that the ethanolic extract of Uncaria tomentosa is more effective as an 
apoptosis inducer than the aqueous extract of Uncaria tomentosa.
During apoptosis, DNA fragmentation is one of the most important structural 
changes.  To show whether DNA fragmentation is present or not, a TUNEL assay was 
used.  Basically, free 3’-OH terminal ends of DNA will appear due to DNA strand breaks
during DNA fragmentation and these ends will be labeled using terminal transferase and
the TdT label and appear as stained nuclei. Consequently, this will be visualized under
the fluorescence microscope (45).  The cells were treated with Uncaria tomentosa at 
different concentrations and different time points then incubated with TUNEL mixture 
and then the fluorescence microscope was used to visualize them.  After 72 h, the cells
treated with the ethanolic extract showed DNA fragmentation compared to control cells 
and the Uncaria tomentosa aqueous extracts.  As a result, the ethanolic extract of 
Uncaria tomentosa was shown to be more effective in causing DNA fragmentation than 
the water extracts. 
To confirm that the cells were dying by apoptosis in response to treatment with 
Uncaria tomentosa extract, more biological experiments were done such as flow 
cytometer by propidium iodide (PI) staining.  This experiment shows apoptotic cells as an 
increase in the sub-G1 DNA peak because the apoptotic cell fragments have lower DNA 
content (46).  The quantification of the cells in the sub-G1 population was determined 
after treatment with 1% of both extractions of Uncaria tomentosa.  After 72 h treatment,
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especially with the ethanolic extract, the percentage of apoptotic cells was around 70% 
compared to the negative control.  This confirms the ability of the ethanolic extract of 
Uncaria tomentosa to induce a large sub-G1 peak due to the increase in the apoptotic cell
population.
Further studies such as immunoblot assays were used to show that Uncaria 
tomentosa treatment of B16-BL6 cells able to initiate the activity of the pro-apoptotic 
caspase-3 and that will confirm the apoptosis induction by Uncaria tomentosa.  Our 
results showed that cells treated with 1% of ethanolic extract of Uncaria tomentosa
showed cleavage of caspase-3.
5.4. Characterization of Uncaria tomentosa
Identifying the components of Uncaria tomentosa extracts by HPLC helps to 
profile the phytochemical characteristics of Uncaria tomentosa.   In previous studies, the 
HPLC results showed different active components, which played an important role in the 
biological activities. For example, the alkaloids were shown to express an immune 
stimulating activity and many of the quinovic acid glycosides have an anti- inflammatory 
activity.  Also, many studies reported the presence of polyhydroxylated triterpenes in 
Uncaria tomentosa that has activity in this plant and its extracts.  Both pharmacological 
and clinical demonstration of this plant showed that the alkaloids and quinovic acid 
glycosides have the most important biological activities.  Most of the commercial drugs 
from this plant must contain those classes of compounds. (51)
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In our study, the main objective of the Uncaria tomentosa separation was to 
identify unknown components that are responsible for the anti-cancer activity in Uncaria 
tomentosa.  Profiles of each fraction of the Uncaria tomentosa were created to 
characterize those fractions for future characterization and insure their bioactivity by 
themselves or in combination with other active components.
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Chapter 6:  Conclusion
The treatment of murine melanoma B16- BL6 cells with Uncaria tomentosa
extracts significantly inhibited cell proliferation and both ethanolic and aqueous extracts 
had similar anti-proliferative effects on malignant and non-malignant cell lines.  From 
our experimental results, we could identify the mechanism of action of Uncaria 
tomentosa and these results showed that the ethanolic extract appeared to kill cells by 
apoptosis. From the cell staining we saw the morphological modifications that 
emphasized the apoptosis characteristics, such as membrane blebbs and chromatin 
condensation.  In addition, the increase in the sub-G1 peak, because of the increase in the 
number of apoptotic cells, would support the idea that the cells undergo apoptosis by 
studying the cell cycle profile.   Moreover, the TUNEL assay confirmed one of the most 
important characters of apoptosis, which is DNA fragmentation.  This experiment 
showed DNA fragmentation in cells treated with the ethanolic extract of Uncaria 
tomentosa.  All of these experiments confirmed that treatment of cells with Uncaria
tomentosa promotes cell death via enhancing cellular apoptosis.
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Appendix  
Uncaria tomentosa inhibits cell migration in high concentration of ethanol extract in 
different time points
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